Maze Therapeutics (MAZE) Non-Current Assets (2024 - 2026)

Maze Therapeutics has disclosed Non-Current Assets across 3 years of filings, most recently posting $39.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $39.9 million, up 20.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $150.5 million (changed N/A YoY), and the FY2025 annual result was $47.4 million, up 21.97% from the prior year.
• Non-Current Assets came in at $39.9 million for Q1 2026 at Maze Therapeutics, down from $47.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $47.4 million in Q4 2025 to a low of $30.8 million in Q3 2025.
• The 3-year median for Non-Current Assets is $36.0 million (2024), against an average of $37.1 million.
• Across the five-year window, Non-Current Assets advanced 21.97% in 2025 and advanced 20.52% in 2026, its largest moves.
• Maze Therapeutics' Non-Current Assets stood at $38.9 million in 2024, then increased by 21.97% to $47.4 million in 2025, then slipped by 15.78% to $39.9 million in 2026.
• The last three Non-Current Assets figures came in at $39.9 million (Q1 2026), $47.4 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.